<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04274426</url>
  </required_header>
  <id_info>
    <org_study_id>AGO-OVAR 2.34</org_study_id>
    <secondary_id>2018-004207-39</secondary_id>
    <nct_id>NCT04274426</nct_id>
  </id_info>
  <brief_title>Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer</brief_title>
  <acronym>MIROVA</acronym>
  <official_title>A Randomized Phase II Trial of Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer Eligible for Platinum-based Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGO Research GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AGO Research GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, two-arm, open-label, comparative phase II trial of
      Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian
      cancer eligible for platinum-based chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      136 patients will be randomized into the follow-ing two treatment arms as specified below:

      Arm A: Control arm Platinum-based chemotherapy Arm B: Carboplatin + Mirvetuximab soravtansine
      (IMGN853)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS) defined as the time from randomization to progressive disease (PD) or death, whichever occurs earlier. PD is based on investigator assess-ment using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).</measure>
    <time_frame>Up to 2.5 years. From date of randomization until date of progressive disease (PD) or death, whichever occurs earlier.</time_frame>
    <description>PD is based on investigator assessment using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Up to 2.5 years. From date of randomization until date of death from any cause.</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>Up to 2.5 years. From date of randomization to date of death death from any cause.</time_frame>
    <description>Objective response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy regarding PFS</measure>
    <time_frame>Up to 2.5 years. From date of randomization to date of death from any cause.</time_frame>
    <description>Efficacy regarding Progression Free Survival depending on histologic subtype</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy regarding OS</measure>
    <time_frame>Up to 2.5 years. From date of randomization to date of death from any cause.</time_frame>
    <description>Efficacy regarding Overall Survival depending on histologic subtype</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy regarding ORR</measure>
    <time_frame>Up to 2.5 years. From date of randomization to date of death from any cause.</time_frame>
    <description>Efficacy regarding Objective Response Rate depending on histologic subtype</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serological progressive disease</measure>
    <time_frame>Up to 2.5 years. From date of randomization to date of death death from any cause.</time_frame>
    <description>Time to serological progressive disease according to GCIG criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first subsequent treatment (TFST)</measure>
    <time_frame>Up to 2.5 years. From date of randomization to date of death from any cause.</time_frame>
    <description>Time to first subsequent treatment (TFST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to second subsequent treatment (TSST)</measure>
    <time_frame>Up to 2.5 years. From date of randomization until date of death from any cause.</time_frame>
    <description>Time to second subsequent treatment (TSST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes</measure>
    <time_frame>Up to 2.5 years. From date of randomization until date of death from any cause.</time_frame>
    <description>Quality of Life (EORTC C-30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes</measure>
    <time_frame>Up to 2.5 years. From date of randomization until date of death from any cause.</time_frame>
    <description>Quality of Life (EORTC OV28)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Up to 2.5 years. From date of randomization until date of death from any cause through study completion.</time_frame>
    <description>Safety and tolerability of the used drugs evaluated by NCI CTCAE v5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Control arm with Platinum-based chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carboplatin (AUC5, d1) as monotherapy q21d
Carboplatin (AUC5, d1) combined with pegylated liposomal doxorubicin (PLD) (30 mg/m², d1) q28d
Carboplatin (AUC4, d1) combined with gemcitabine (1000 mg/m2, d1 &amp; d8) q21d
Carboplatin (AUC5, d1) combined with paclitaxel (175 mg/m², d1) q21d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carboplatin + Mirvetuximab soravtansine (IMGN853)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin (AUC5, d1) + Mirvetuximab soravtansine (IMGN853) 6 mg/kg IV d1 x 6 cycles q21d, followed by subsequent monotherapy of Mirvetuximab soravtansine (IMGN853) 6 mg/kg IV q3w until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin will administered by intravenous route</description>
    <arm_group_label>Carboplatin + Mirvetuximab soravtansine (IMGN853)</arm_group_label>
    <arm_group_label>Control arm with Platinum-based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated liposomal doxorubicin (PLD)</intervention_name>
    <description>PLD will be administered by intravenous route</description>
    <arm_group_label>Control arm with Platinum-based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine will be administered by intravenous route</description>
    <arm_group_label>Control arm with Platinum-based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel will be administered by intravenous route</description>
    <arm_group_label>Control arm with Platinum-based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirvetuximab Soravtansine</intervention_name>
    <description>Mirvetuximab Soravtansine will be administered by intravenous route</description>
    <arm_group_label>Carboplatin + Mirvetuximab soravtansine (IMGN853)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All patients must have a pathologically documented, definite diagnosis of epithelial
             cancer of the ovary, the fallopian tube or the peritoneum

          2. Relapsed disease with a platinum-free interval &gt;3 months

          3. All histologic subtypes of ovarian carcinoma including carcinosarcoma (malignant mixed
             Mullerian tumors, MMMT)

          4. Patients with wildtype BRCA1/2 mutation status or with a deleterious BRCA1/2 mutation
             in germline or somatic testing if they underwent PARP inhibitor therapy in previous
             treatment line.

          5. Patients must be willing to provide archival tumor tissue from current relapse or
             previous surgeries/biopsies for central confirmation of FRα high status by PS2+
             scoring:

             all tumors must exhibit ≥75% of tumor cells with FRα membrane staining and ≥ 2+
             intensity by immunohistochemistry (IHC) using the Ventana FOLR1 (FOLR1 2.1) CDx assay.

          6. Patients must have measurable disease or evaluable disease in combination with GCIG
             CA-125 criteria.

          7. Patients had one or more prior lines of chemotherapy. The last line of chemotherapy
             should have included platinum and has resulted in a partial or complete response.

          8. Major surgery (not including placement of vascular access device, tumor punch/scrape
             biopsies or secondary wound closure) must be completed four weeks prior to Day 1.

          9. Patients must have adequate hematological, liver, cardiac and kidney function:

               1. Hemoglobin ≥ 10.0 g/dL.

               2. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

               3. Platelet count ≥ 100 x 109/L.

               4. Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN).

               5. Aspartate aminotransferase/Serum Glutamic Oxaloacetic Transaminase (ASAT/SGOT))
                  and Alanine aminotransferase/Serum Glutamic Pyruvate Transaminase (ALAT/SGPT)) ≤
                  2.5 x ULN, unless liver metastases are present in which case they must be ≤ 5 x
                  ULN.

               6. Serum creatinine ≤ 1.5 x institutional ULN and glomerular filtration rate of at
                  least 40 ml/minute according to Cockroft-Gault formula.

         10. Patient is female and ≥18 years of age at the time of the first screening visit.

         11. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.

         12. Patients must be willing and able to sign the informed consent form, and to adhere to
             the study visit schedule and other protocol requirements.

         13. For women of childbearing potential (a woman is considered of childbearing potential
             (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless
             permanently sterile. Permanent sterilization methods include hysterectomy, bilateral
             salpingectomy and bilateral oophorectomy) must use a highly effective method of
             contraception. Such methods include:

               1. Combined (estrogen and progestogen containing) hormonal contraception associated
                  with inhibition of ovulation:

                    -  oral

                    -  intravaginal

                    -  transdermal

               2. Progestogen-only hormonal contraception associated with inhibition of ovula-tion:

                    -  oral

                    -  injectable

                    -  implantable

               3. Intrauterine device (IUD)

               4. Intrauterine hormone-releasing system (IUS)

               5. Bilateral tubal occlusion

               6. Vasectomized partner

               7. Sexual abstinence

        Exclusion Criteria:

          1. Non-epithelial tumor origin of the ovary, the fallopian tube or the peritoneum (i.e.
             germ cell tumors)

          2. Ovarian tumors of low malignant potential (e.g. borderline tumors).

          3. Unknown BRCA status.

          4. Patients who are planned to receive bevacizumab for the current relapse.

          5. Other malignancy within the last 3 years (except cervix or breast in situ carcinoma,
             type I stage I endometrial cancer)

          6. Patients who underwent surgery for the current relapse with macroscopic complete
             resection

          7. Prior systemic anticancer therapy within 28 days before randomization

          8. Prior treatment with folate receptor-targeting investigational agents is not allowed.

          9. Patients with &gt; Grade 1 peripheral neuropathy.

         10. Serious concurrent illness or clinically-relevant active infection

         11. Previous clinical diagnosis of non-infectious interstitial lung disease, including
             non-infectious pneumonitis.

         12. Active or chronic corneal disorders such as Sjogren's syndrome, Fuchs corneal
             dystrophy (requiring treatment), history of corneal transplantation, active herpetic
             keratitis, active ocular conditions requiring on-going treatment/monitoring such as
             uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal
             injections, active diabetic retinopathy with macular edema, macular degeneration,
             presence of papilledema, and /or monocular vision. Active or chronic corneal disorder

         13. Required use of folate-containing supplements (e.g. folate deficiency)

         14. Women of childbearing potential (WOCBP) not protected by highly effective
             contraceptive methods.

         15. Pregnant and/or breast-feeding women.

         16. Known hypersensitivity to Carboplatin.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michaela Fredrich</last_name>
    <phone>+49 611 880467</phone>
    <phone_ext>42</phone_ext>
    <email>mfredrich@ago-oavr.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charite Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Jalid Sehouli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Eva-Katharina Egger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl-Gustav-Carus an der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Tanja Fehm</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evangelische Kliniken-Essen-Mitte</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Philipp Harter</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Pawel Mach</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Ahmed El.Balat</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Ingo Runnebaum</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Kassel</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Gabriele Feisel-Schwickardi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Dirk Bauerschlag</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Krefeld</name>
      <address>
        <city>Krefeld</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Gunther Rogmans</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth-Krankenhaus GmbH</name>
      <address>
        <city>Köln-Hohenlind</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Daniel Rein</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Marburg</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rotkreuzklinikum München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Martin Poelcher</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>TU München, Klinikum recht der Isar</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Holger Bronger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Tübingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Nikolaus de Gregorio</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ago-ovar.de/</url>
    <description>Related Info</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Maytansine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

